OIG Advisory Opinion 26-14 Offers Another Favorable Path for Patient Access Through Sponsored Testing
On June 10, 2026, the Department of Health and Human Services Office of Inspector General (OIG) issued Advisory Opinion 26-14 (AO 26-14), another favorable advisory opinion (its fourth in as many…
Read the full articleYou might also wanna read
Oversight of Laboratory Developed Tests One Year After ACLA v. FDA: Assessing Legislative Proposals in Context
Our latest Advisory examines the current state of laboratory developed test oversight, highlights key developments since the court’s decisio
HHS-OIG Issues Unfavorable Advisory Opinion on Pay-to-Play Referral Software Platform Arrangement
Highlights The U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) released an unfavorable advisory opinion f
New HIPAA Security Rule Delayed Until 2027
The U.S. Department of Health and Human Services' Office for Civil Rights (OCR) reportedly has updated its regulatory agenda. According to t
OIG Raises Anti-Kickback Concerns About Subscription-Based Referral Management Platforms
Key Takeaways: OIG’s Advisory Opinion 26-15 asserts that a subscription-based referral management software arrangement could implicate the f
FDA Issues Revised Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drugs and Biological Products
On June 22, 2026, the U.S. Department of Health and Human Services (HHS) unveiled Operation TrialBlazer, a department-wide effort to acceler
FDA Issues Draft Guidance on Responding to Form 483 Observations
In March 2026, the U.S. Food and Drug Administration (FDA or the Agency) issued the draft guidance for industry, Responding to FDA Form 483
Comments
Sign in to join the conversation.
No comments yet. Be the first.